Home ＞ Company Overview ＞ Company History
- Apr. 2002
- Established in the Port Island of Kobe, Japan with the aim at commercialization of cell therapy using embryonic and somatic stem cells.
- Apr 2002
- Exclusively licenced in Asian territories of fourteen patents or patent applications by Stem Cell Science Ltd. , Australia.
- May 2002
- Start collaborative researches with Riken CDB and participation in the project of"CREATE".
- Jul. 2003
- Set up of laboratory at the Translational Research Informatics center, Kobe, Japan
- Apr. 2004
- Contracted collaborative research agreement with Fuji Rebio Inc.
- May 2004
- Contracted distribution agreement with Dainippon Pharmaceutical Co., Ltd for sales in Japan of non-serum and non-feeder medium ‘CultiCell’.
- Mar. 2005
- The Minister of Education, Culture, Sports, Science and Technology of Japan approved our human ES cell research carried out in collaboration with the Multipotent Stem Cell Research Group within Riken CDB
- Sep. 2005
- Establishment of the cell processing center of the cGMP compliance within the facilities of the Institute for Biomedical Research and Innovation, Kobe, Japan
- Nov. 2005
- Execution of license agreement on human multipotent adipose-derived stem cell for use in the field of cell therapy
- Feb. 2006
- The Minister of Education, Culture, Sports, Science and Technology of Japan approved our human ES cell research project using human ES cell in collaboration with the Stem Cell Research Group within the Riken CDB
- Apr. 2006
- New Research Laboratory for human cell research was opened within the facility of Business Support Center for Biomedical Research Activities in Kobe, Japan
- Sep. 2006
- Execution of license agreement on human multipotent adipose-derived stem cell for research use purpose.
- Apr. 2007
- Execution of license agreement with Celogos, France on the technology for autologous myoblast transplantation for treatment of Stress urinary incontinence exclusively in Japan.
